Amanda Haltiwanger
Family · Prosperity, SCNPI 1649432477
Payments from drug & device makers
Across 344 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$641
- AstraZeneca$509
- Pfizer$485
- Novo Nordisk$429
- GSK$360
- Lilly USA, LLC$251
- plus $3K from 46 others
What the payments were for
- Food & beverage$5,547100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,547 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 91 | $100,549 |
| EliquisApixaban | 37 | $34,135 |
| MounjaroTirzepatide | 14 | $22,708 |
| JardianceEmpagliflozin | 15 | $18,385 |
| LinzessLinaclotide | 17 | $17,103 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $16,370 |
| XareltoRivaroxaban | 25 | $15,872 |
| FarxigaDapagliflozin Propanediol | 17 | $14,199 |
| MyrbetriqMirabegron | 12 | $13,894 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $11,973 |
| JanuviaSitagliptin Phosphate | 11 | $11,494 |
| Celecoxib | 33 | $3,918 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 61 | $2,759 |
| Atorvastatin Calcium | 257 | $2,419 |
| Levothyroxine Sodium | 219 | $2,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $429 | $100,54991 claims |
| PfizerEliquis | $485 | $34,13537 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $509 | $26,17328 claims |
| Lilly USA, LLCMounjaro | $251 | $22,70814 claims |
| AbbVieLinzess, Synthroid | $641 | $18,69743 claims |
| Boehringer IngelheimJardiance | $155 | $18,38515 claims |
| GSKTrelegy Ellipta | $360 | $16,37020 claims |
| Astellas Pharma US IncMyrbetriq | $87 | $13,89412 claims |
| MerckJanuvia | $115 | $11,49411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.
Other family in Prosperity
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
- Doris ReidSimpsonville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.